Arcturus Therapeutics Hits New 52-Week Low at $7.76

Arcturus Therapeutics Holdings, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 7.76 on November 13, 2025. This significant decline reflects a challenging year for the company, with a staggering 75.63% drop in its stock price over the past year, contrasting sharply with the S&P 500's 14.49% gain during the same period.
The company's financial metrics indicate ongoing difficulties, including a negative return on equity of -10.01% and a debt-to-equity ratio of -1.07. Arcturus has reported a decline in net sales of 3.8%, with recent quarterly results showing a net profit of -USD 5.35 million, marking a 69.04% decrease. The stock's price-to-book ratio stands at 2.10, suggesting that the market is valuing the company at a premium relative to its book value.

With a market capitalization of USD 484 million, Arcturus continues to face headwinds, as evidenced by its consistent underperformance against the S&P 500 over the last three years. The company has not paid dividends, further highlighting its current financial challenges.